Swedish Orphan Biovitrum, an international specialty biopharmaceutical company dedicated to rare diseases, based in Stockholm, completed the acquisition of Dova Pharmaceuticals, a clinical-stage pharmaceutical company, for $915m. “The cadence of upcoming launches and approvals across indications and regions that Doptelet provides, enables us to further accelerate growth in our haematology franchise. There is a large unmet medical need within thrombocytopenia and for us this is a great opportunity to be able to give patients access to new and improved treatments. Furthermore, we are excited to welcome the 125 professionals from Dova who will greatly strengthen Sobi’s haematology infrastructure and broaden our value chain in the US,” Guido Oelkers, Sobi President and Chief Executive Officer.